EA9171 / BLAST MRD CML 1
BLAST MRD CML 1: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML) - A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD
Physician and Research Staff Educational Material
This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material. Scroll down for patient educational material.
Patient Educational Material
Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material. For sites utilizing local IRBs, please submit this in accordance with your local IRB policies prior to use.